Skip to main content
SpringerLink
Log in

OCT in Toxic and Nutritional Optic Neuropathies

  • Chapter
  • First Online:
OCT in Central Nervous System Diseases

  • 1884 Accesses

Abstract

Despite the recent developments of OCT in neuro-ophthalmology, its use for diagnosing and monitoring nutritional and toxic optic neuropathies is still limited, due to the lack of powered, longitudinal studies. Small series have suggested that OCT may be useful in various toxic optic neuropathies in the acute stage, disclosing subtle retinal nerve fibre layer thickening, ophthalmoscopically undetectable. At later stages, retinal nerve fibre layer thinning affects the papillomacular bundle, and then, all quadrants, but only rarely before visual loss. Macular volume OCT studies have suggested that in toxic optic neuropathies, the primary site of injury may involve the retinal ganglion cells layers. Retinal nerve fibre layer thinning in the nasal quadrant in patients treated with vigabatrin appears to be predictive of visual field constriction.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Grzybowski A, Zulsdorff M, Wilhelm H, Tonagel F. Toxic optic neuropathies: an updated review. Acta Ophthalmol. 2015;93:402–10. doi:10.1111/aos.12515.

    Article  PubMed  Google Scholar 

  2. Wang MY, Sadun AA. Drug-related mitochondrial optic neuropathies. J Neuroophthalmol. 2013;33:172–8.

    Article  CAS  PubMed  Google Scholar 

  3. Zoumalan CI, Agarwal M, Sadun AA. Optical coherence tomography can measure axonal loss in patients with ethambutol-induced optic neuropathy. Graefes Arch Clin Exp Ophthalmol. 2005;243:410–6.

    Article  PubMed  Google Scholar 

  4. Sihota R, Sony P, Gupta V, et al. Diagnostic capability of optical coherence tomography in evaluating the degree of glaucomatous retinal nerve fiber damage. Invest Ophthalmol Vis Sci. 2006;47:2006–10.

    Article  PubMed  Google Scholar 

  5. Rebolleda G, Noval S, Contreras I, et al. Optic disc cupping after optic neuritis evaluated with optic coherence tomography. Eye (Lond). 2008;23:890–4.

    Article  Google Scholar 

  6. Medeiros FA, Moura FC, Vessani RM, Susanna R. Axonal loss after traumatic optic neuropathy documented by optical coherence tomography. Am J Ophthalmol. 2003;135:406–8.

    Article  PubMed  Google Scholar 

  7. Fisher JB, Jacobs DA, Markowitz CE, et al. Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis. Ophthalmology. 2006;113:324–32.

    Article  PubMed  Google Scholar 

  8. Kozak SF, Inderlied CB, Hsu HY, et al. The role of copper on ethambutol’s antimicrobial action and implications for ethambutol-induced optic neuropathy. Mycobacteriology. 1998;30:83–7.

    CAS  Google Scholar 

  9. Masvidal D, Parrish II RK, Lam BL. Structural-functional dissociation in presumed ethambutol optic neuropathy. J Neuroophthalmol. 2010;30:305–10.

    Article  PubMed  Google Scholar 

  10. Sadun AA, Wang MY. Ethambutol optic neuropathy: how we can prevent 100,000 new cases of blindness each year. J Neuroophthalmol. 2008;28:265–8.

    Article  PubMed  Google Scholar 

  11. Sivakumaran P, Harrisson AC, Marschner J. Ocular toxicity from ethambutol: a review of four cases and recommended precautions. N Z Med J. 1998;13:428–30.

    Google Scholar 

  12. Kinoshita J, Iwata N, Maejima T, Kimotsuki T, Yasuda M. Retinal function and morphology in monkeys with ethambutol-induced optic neuropathy. Invest Ophthalmol Vis Sci. 2012;53:7052–62.

    Article  PubMed  Google Scholar 

  13. Chai SJ, Foroozan R. Decreased retinal nerve fibre layer thickness detected by optical coherence tomography in patients with ethambutol-induced optic neuropathy. Br J Ophthalmol. 2007;91:895–7.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Kim U, Hwang JM. Early stage ethambutol optic neuropathy: retinal nerve fiber layer and optical coherence tomography. Eur J Ophthalmol. 2009;19:466–9.

    PubMed  Google Scholar 

  15. Han J, Byun MK, Lee J, Han SY, Lee JB, Han SH. Longitudinal analysis of retinal nerve fiber layer and ganglion cell-inner plexiform layer thickness in ethambutol-induced optic neuropathy. Graefes Arch Clin Exp Ophthalmol. 2015.

    Google Scholar 

  16. Vieira LM, Silva NF, et al. Retinal ganglion cell layer analysis by optical coherence tomography in toxic and nutritional optic neuropathy. J Neuroophthalmol. 2015;35(3):242–5.

    Google Scholar 

  17. Fanta H, Mayer-Oberditsch l. Ein Beitrag zur Pathologie im Sehnerven bei Methylalkoholvergiftung (Tierversuche). Klin Monatsbl Augenheilkd. 1953;122:288–394.

    Google Scholar 

  18. Sanaei-zadeh H, Zamani N, Shadnia SH. Outcomes of visual disturbances after methanol poisoning. Clin Toxicol (Phila). 2011;49:102–7.

    Article  Google Scholar 

  19. Brent J, McMartin K, Phillips S, Aaron C, Kulig K. Fomepizole for the treatment of methanol poisoning. N Engl J Med. 2001;344:424–9.

    Article  CAS  PubMed  Google Scholar 

  20. Pakravan M, Sanjari N. Erythropoietin treatment for methanol optic neuropathy. J Neuroophthalmol. 2012;32:325–8.

    Article  PubMed  Google Scholar 

  21. Fujihara M, Kikuchi M, Kurimoto Y. Methanol-induced retinal toxicity patient examined by optical coherence tomography. Jpn J Ophthalmol. 2006;50:239–41.

    Article  PubMed  Google Scholar 

  22. Cullom ME, Heher KL, Miller NR, Savino PJ, Johns DR. Leber's hereditary optic neuropathy masquerading as tobacco-alcohol amblyopia. Arch Ophthalmol. 1993;111:1482–5.

    Article  CAS  PubMed  Google Scholar 

  23. Mackey D, Howell N. Tobacco amblyopia. Am J Ophthalmol. 1994;117:817–9.

    Article  CAS  PubMed  Google Scholar 

  24. Johns DR, Heher KL, Miller NR, Smith KH. Leber's hereditary optic neuropathy. Clinical manifestations of the 14484 mutation. Arch Ophthalmol. 1993;111:495–8.

    Article  CAS  PubMed  Google Scholar 

  25. Freeman AG. Optic neuropathy and chronic cyanide intoxication: a review. J R Soc Med. 1988;81:103–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  26. Grzybowski A, Holder GE. Tobacco optic neuropathy (TON) - the historical and present concept of the disease. Acta Ophthalmol. 2011;89:495–9.

    Article  PubMed  Google Scholar 

  27. Behbehani R, Sergott RC, Savino PJ. Tobacco-alcohol amblyopia: a maculopathy? Br J Ophthalmol. 2005;89:1543–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Kee C, Hwang J-M. Optical coherence tomography in a patient with tobacco-alcohol amblyopia. Eye (Lond). 2008;22:469–70.

    Article  CAS  Google Scholar 

  29. Moura FC, Monteiro ML. Evaluation of retinal nerve fiber layer thickness measurements using optical coherence tomography in patients with tobacco-alcohol-induced toxic optic neuropathy. Indian J Ophthalmol. 2010;58:143–6.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Grzybowski A. Tobacco amblyopia: does it really exist? Eye (Lond). 2007;21:1448–9.

    Article  CAS  Google Scholar 

  31. Grzybowski A, Pieniazek M. Tobacco-alcohol amblyopia: nonexistent entity. Ind Psychiatry J. 2012;21:79.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Grzybowski A, Pieniążek M. Tobacco-alcohol amblyopia does not exist. Acta Ophthalmol. 2014;92:e77–8.

    Article  PubMed  Google Scholar 

  33. Grzybowski A. Mitochondrial optic neuropathies: additional facts and concepts. Clin Experiment Ophthalmol. 2013. doi:10.1111/ceo.

    Google Scholar 

  34. Grzybowski A, Pieniążek M. Tobacco-alcohol amblyopia–nonexistent entity cannot be diagnosed. J Neurol Sci. 2013;332:156.

    Article  PubMed  Google Scholar 

  35. Macaluso DC, Shults WT, Fraunfelder FT. Features of amiodarone-induced optic neuropathy. Am J Ophthalmol. 1999;127:610–2.

    Article  CAS  PubMed  Google Scholar 

  36. Martínez-LóPez-Portillo A, Martínez-Gamero BO, Mohamed-Noriega J, Cavazos-Adame H, Mohamed-Hamsho J. Behaviour of disc oedema during and after amiodarone optic neuropathy: case report. J Clin Diagn Res. 2014;8:VD04–5.

    PubMed  PubMed Central  Google Scholar 

  37. Orssaud C, Roche O, Dufier JL. Nutritional optic neuropathies. J Neurol Sci. 2007;262:158–64.

    Article  CAS  PubMed  Google Scholar 

  38. Sawicka-Pierko A, Obuchowska I, Hady RH, Mariak Z, Dadan J. Nutritional optic neuropathy following bariatric surgery. Wideochir Inne Tech Maloinwazyjne. 2014;9(4):662–6.

    Google Scholar 

  39. Becker M, Masterson K, Delavelle J, Viallon M, Vargas MI, Becker CD. Imaging of the optic nerve. Eur J Radiol. 2010;74:299–313.

    Article  PubMed  Google Scholar 

  40. Gratton SM, Lam BL. Visual loss and optic nerve head swelling in thiamine deficiency without prolonged dietary deficiency. Clin Ophthalmol. 2014;8:1021–4.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Pineles SL. Combined optic neuropathy and myelopathy secondary to copper deficiency. Surv Ophthalmol. 2010;55:386–92.

    Article  PubMed  Google Scholar 

  42. Naismith RT, Shepherd JB, Weihl CC, Tutlam NT, Cross AH. Acute and bilateral blindness due to optic neuropathy associated with copper deficiency. Arch Neurol. 2009;66:1025–7.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Spinazzi M, De Lazzari F, Tavolato B, Angelini C, Manara R, Armani M. Myelo-optico-neuropathy in copper deficiency occurring after partial gastrectomy: do small bowel bacterial overgrowth syndrome and occult zinc ingestion tip the balance? J Neurol. 2007;254:1012–7.

    Article  PubMed  Google Scholar 

  44. Woon C, Tang RA, Pardo G. Nutrition and optic nerve disease. Semin Ophthalmol. 1995;10:195–202.

    Article  CAS  PubMed  Google Scholar 

  45. Eke T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. BMJ. 1997;314:180–1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Daneshvar H, Racette L, Coupland SG, Kertes PJ, Guberman A, Zackon D. Symptomatic and asymptomatic visual loss in patients taking vigabatrin. Ophthalmology. 1999;106:1792–8.

    Article  CAS  PubMed  Google Scholar 

  47. Lawden MC, Eke T, Degg C, Harding GF, Wild JM. Visual field defects associated with vigabatrin therapy. J Neurol Neurosurg Psychiatry. 1999;67:716–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Miller NR, Johnson MA, Paul SR, Girkin CA, Perry JD, Endres M, et al. Visual dysfunction in patients receiving vigabatrin: clinical and electrophysiologic findings. Neurology. 1999;53:2082–7.

    Article  CAS  PubMed  Google Scholar 

  49. Wild JM, Ahn HS, Baulac M, Bursztyn J, Chiron C, Gandolfo E, et al. Vigabatrin and epilepsy: lessons learned. Epilepsia. 2007;48:1318–27.

    Article  CAS  PubMed  Google Scholar 

  50. Versino M, Veggiotti P. Reversibility of vigabratin-induced visual-field defect. Lancet. 1999;354:486.

    Article  CAS  PubMed  Google Scholar 

  51. Frisen L, Malmgren K. Characterization of vigabatrin-associated optic atrophy. Acta Ophthalmol Scand. 2003;81:466–73.

    Article  PubMed  Google Scholar 

  52. Wild JM, Robson CR, Jones AL, Cunliffe IA, Smith PE. Detecting vigabatrin toxicity by imaging of the retinal nerve fiber layer. Invest Ophthalmol Vis Sci. 2006;47:917–24.

    Article  PubMed  Google Scholar 

  53. Lawthom C, Smith PE, Wild JM. Nasal retinal nerve fiber layer attenuation: a biomarker for vigabatrin toxicity. Ophthalmology. 2009;116:565–71.0.

    Article  PubMed  Google Scholar 

  54. Moseng L, Sæter M, Mørch-Johnsen GH, Hoff JM, Gajda A, Brodtkorb E, Midelfart A. Retinal nerve fibre layer attenuation: clinical indicator for vigabatrin toxicity. Acta Ophthalmol. 2011;89:452–8.

    Article  PubMed  Google Scholar 

  55. Kjellström U, Andréasson S, Ponjavic V. Attenuation of the retinal nerve fibre layer and reduced retinal function assessed by optical coherence tomography and full-field electroretinography in patients exposed to vigabatrin medication. Acta Ophthalmol. 2014;92:149–57.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Ophthalmology, CHU Reims, Reims, France

    Carl Arndt & Tony Garcia

  2. Singapore Eye Research Institute, Singapore, Singapore

    Sourabh Sharma & Dan Milea

  3. Singapore National Eye Centre, Singapore, Singapore

    Dan Milea

  4. CHU Angers, Angers, France

    Dan Milea

  5. Duke-NUS, Singapore, Singapore

    Dan Milea

  6. Professor of Ophthalmology, Head of Ophthalmology Department, Poznan City Hospital, Poznan, Poland

    Andrzej Grzybowski MD, PhD, MBA

  7. Chair of Department of Ophthalmology, University of Warmia and Mazury, Olsztyn, Poland

    Andrzej Grzybowski MD, PhD, MBA

Authors
  1. Carl Arndt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sourabh Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dan Milea
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tony Garcia
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Andrzej Grzybowski MD, PhD, MBA
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carl Arndt .

Editor information

Editors and Affiliations

  1. Head of Ophthalmology Department, Professor of Ophthalmology,, Poznań, Poland

    Andrzej Grzybowski

  2. Studio Oculistico d’Azeglio, Bologna, Italy

    Piero Barboni

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Arndt, C., Sharma, S., Milea, D., Garcia, T., Grzybowski, A. (2016). OCT in Toxic and Nutritional Optic Neuropathies. In: Grzybowski, A., Barboni, P. (eds) OCT in Central Nervous System Diseases. Springer, Cham. https://doi.org/10.1007/978-3-319-24085-5_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-24085-5_12

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-24083-1

  • Online ISBN: 978-3-319-24085-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation